

First series "Immeran" 0.25, 0.5 mg/kg Intraperitoneal injection or Favipiravir 1200 mg/kg and 500 mg/kg orally

Second series "Immeran" 0.5, 1.0 mg/kg Intraperitoneal injection

Figure 1. Flowchart of animal experiments 1 and 2.

Table. Cumulative severity scoring from H&E stained slides of lungs from golden hamsters with SARS-CoV-2-associated interstitial pneumonia and different treatment dosage and regimes using “Immeran” drug.

| Criterion for assessing the severity of the inflammatory process in the lungs | Animal group | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 1 viral control group | | | | | 2 one intraperitoneal injection 0.5 mL of 250 µg/kg of “Immeran” 24 hours before infection | | | | | 3 one intraperitoneal injection 0.5 mL of 500 µg/kg of “Immeran” 24 hours before infection | | | | | 4 one intraperitoneal injection 0.5 mL of 250 µg/kg of “Immeran” 1 hour after infection and four days once every other day | | | | | 5 one intraperitoneal injection 0.5 mL of 500 µg/kg of “Immeran” 1 hour after infection and four days once every other day | | | | | 6 Favipiravir orally 1200 mg/kg 1 hour before infection, then 500 mg/kg twice a day for 4 days | | | | |
| Animal № in group | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| Number of animals in group without inflammatory changes in lungs | 0 | | | | | 0 | | | | | 1 | | | | | 2 | | | | | 3 | | | | | 0 | | | | |
| Prevalence of inflammation (in points from 0 to 3) | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 0 | 1 | 2 | 3 | 0 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 |
| Extensive airless foci of pneumonia (in points from 0 to 3) | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 1 | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Small scattered foci of pneumonia (in points from 0 to 3) | 2 | 2 | 3 | 3 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 0 | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 |
| Bronchitis, bronchiolitis (in points from 0 to 3) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 0 | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |




Figure 2. Statistical analysis of data from Table 1. Statistical comparisons between groups were done using unpaired Student's t-test ($p < 0.05$, $n = 30$). Group 1 - viral control group, Group 2 - one intraperitoneal injection 0.5 mL of 250 $\mu\text{g/kg}$ of "Immeran" 24 hours before infection, Group 3 - one intraperitoneal injection 0.5 mL of 500 $\mu\text{g/kg}$ of "Immeran" 24 hours before infection, Group 4 - one intraperitoneal injection 0.5 mL of 250 $\mu\text{g/kg}$ of "Immeran" 1 hour after infection and four days once every other day, Group 5 - one intraperitoneal injection 0.5 mL of 500 $\mu\text{g/kg}$ of "Immeran" 1 hour after infection and four days once every other day, Group 6 - Favipiravir orally 1200 mg/kg 1 hour before infection, then 500 mg/kg twice a day for 4 days.




Figure 3. Statistical analysis of virus titer. Statistical comparisons between groups were done using unpaired Student's t-test ($p < 0.05$, $n = 30$). Group 1 - viral control group, Group 2 - one intraperitoneal injection 0.5 mL of 250 $\mu\text{g/kg}$ of "Immeran" 24 hours before infection, Group 3 - one intraperitoneal injection 0.5 mL of 500 $\mu\text{g/kg}$ of "Immeran" 24 hours before infection, Group 4 - one intraperitoneal injection 0.5 mL of 250 $\mu\text{g/kg}$ of "Immeran" 1 hour after infection and four days once every other day, Group 5 - one intraperitoneal injection 0.5 mL of 500 $\mu\text{g/kg}$ of "Immeran" 1 hour after infection and four days once every other day, Group 6 - Favipiravir orally 1200 mg/kg 1 hour before infection, then 500 mg/kg twice a day for 4 days.